{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-027545","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.004835+00:00","generated_at":"2026-05-24T05:31:09.058157+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Traws Pharma reports positive Phase 1 data for COVID-19 drug ratutrelvir; no ritonavir needed","bullets":["Phase 1 data at 600 mg/day for 10 days show trough blood levels ~13x EC50 and >EC90 for 2 days post-treatment.","Ratutrelvir suppressed 18 SARS-CoV-2 strains including nirmatrelvir-resistant and Omicron variants in lab tests.","No requirement for ritonavir boosting due to favorable metabolism, potentially reducing drug-drug interaction risks.","Excellent safety/tolerability in SAD and MAD studies at all doses tested; target Phase 2 dose defined.","Company plans FDA interactions to initiate Phase 2; investor event March 31, 2025 at 10:00 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-027545","json":"https://secwatch.observer/filing/0001104659-25-027545.json","markdown":"https://secwatch.observer/filing/0001104659-25-027545.md","text":"https://secwatch.observer/filing/0001104659-25-027545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/0001104659-25-027545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/tm2510212d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:31:09.058157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}